Retatrutide: Results, Side Effects & FDA Status (2026)

Evidence checked September 16, 2026

Retatrutide is an investigational medicine that activates three hormone receptors involved in appetite and metabolism. It is not FDA-approved. In Lilly’s TRIUMPH-1 trial, the highest-dose group averaged 28.3% weight loss at 80 weeks in the efficacy analysis. That is a substantial result, but it does not establish long-term safety or validate products sold online. [1] [2]

Patients arrive in my consultation room asking about retatrutide by name. Some tell me they are already using it. They have often read a mixture of trial announcements, social media posts, and vendor claims. My goal is to help readers separate those sources and understand what the evidence means for their health, including decisions about surgery after weight loss.

What is retatrutide

Retatrutide, also called LY3437943, is a peptide being developed by Eli Lilly as a once-weekly injection. It activates receptors for glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon. Researchers therefore describe it as a triple receptor agonist. [3]

“Triple G” and “reta” are informal names. “GLP-3” is not the pharmacological name of this treatment: retatrutide targets three different receptors, rather than a third version of GLP-1. Knowing the actual molecule matters when discussing a medication with your physician.

How retatrutide works

The three pathways contribute different effects:

GLP-1: participates in fullness signals and glucose regulation, and can slow stomach emptying.
GIP: contributes to glucose-dependent insulin signaling and the combined metabolic effects of the molecule.
Glucagon: acts on liver and energy-regulation pathways. Its contribution is a major reason researchers are studying this combination. [3] [4]

Retatrutide activates three receptor pathways. This schematic illustrates the targets, not the size of each target’s contribution to weight loss. Sources: Coskun et al. and Lilly Medical. [3] [4]

Preclinical research found that retatrutide increased energy expenditure in obese mice. That supports a biological explanation worth investigating; it does not tell us how many extra calories a person will burn each day. Semaglutide and tirzepatide also affect glucose regulation and metabolism, so describing them as mere appetite suppressants would be misleading. [3] [5] [6]

Retatrutide weight loss results from clinical trials

The early obesity study was published in the New England Journal of Medicine in 2023. The phase 3 figures below come from Lilly’s dated trial announcements. These are group averages in specific study populations, not predictions for an individual. [7] [8] [2] [9]

Study	Participants	Duration	Mean weight loss
Phase 2 obesity	Adults with obesity or overweight without diabetes	48 weeks	24.2% with 12 mg; 2.1% with placebo [7]
TRIUMPH-4	Adults with obesity or overweight and knee osteoarthritis, without diabetes	68 weeks	28.7% with 12 mg; 2.1% with placebo [8]
TRIUMPH-1	Adults with obesity or qualifying overweight, without diabetes	80 weeks	28.3% with 12 mg; 2.2% with placebo [2]
TRIUMPH-2	Adults with obesity or overweight and type 2 diabetes	80 weeks	20.8% with 12 mg; 4.0% with placebo [9]
TRIUMPH-3	Adults with severe obesity and established cardiovascular disease	80 weeks	22.6% with 12 mg; 3.2% with placebo [9]

Phase 3 values use the efficacy estimand, which estimates effects with continued treatment. Studied doses are reported to identify the evidence, not as dosing instructions.

Why does the analysis matter? In TRIUMPH-1, the treatment-regimen analysis, which accounts for discontinuation and other treatment changes, estimated 25.0% loss with 12 mg versus 3.9% with placebo. Presenting only the largest number leaves out useful context. [2]

A selected TRIUMPH-1 extension group with starting BMI of at least 35, who completed the main study and tolerated treatment, reached 30.3% mean loss at 104 weeks in the group initially assigned 12 mg. This is not a result for every participant. [2]

The results deserve attention. They also leave questions about tolerability, maintenance, and outcomes after years of use. Trial participants receive a verified study medicine and structured follow-up; an online vial bearing the same name cannot be assumed to reproduce that experience.

Retatrutide versus tirzepatide and semaglutide

Medicine	Receptor targets	Names readers may recognize
Semaglutide	GLP-1	Wegovy and Ozempic
Tirzepatide	GIP and GLP-1	Zepbound and Mounjaro
Retatrutide	GIP, GLP-1, and glucagon	Investigational LY3437943

Brand names, formulations, doses, and approved uses are not interchangeable. Original obesity-trial benchmarks were 14.9% average loss at 68 weeks with weekly semaglutide 2.4 mg in STEP 1 and 20.9% at 72 weeks with tirzepatide 15 mg in SURMOUNT-1. Those results should not be applied to every Ozempic or Mounjaro regimen. Semaglutide now has additional formulations and doses; these older benchmarks are not a complete ranking of 2026 treatment options. [5] [6] [10] [11]

Retatrutide’s reported weight reductions are promising, but separate trials cannot establish which medicine is best for a particular patient. Participants, duration, analysis methods, and follow-up differ. A direct comparison of retatrutide with tirzepatide, TRIUMPH-5, is underway; its existence corrects the misconception that no head-to-head study exists. [12]

Retatrutide side effects and unresolved safety questions

The phase 2 obesity trial reported mainly gastrointestinal side effects, with more problems at higher doses. It also found dose-related heart-rate increases that peaked at 24 weeks and then declined. Those findings warrant follow-up rather than a claim that the drug is harmless. [7]

In TRIUMPH-4, nausea affected 43.2% of participants receiving 12 mg, diarrhea 33.1%, vomiting 20.9%, and constipation 25.0%. These rates describe that particular trial, not the expected experience of every user. At that dose, 18.2% discontinued because of adverse events, compared with 4.0% on placebo. [8]

Altered skin sensation, or dysesthesia, also deserves attention. It can feel like tingling, burning, or unusual sensitivity. Lilly reported it in 20.9% of the 12 mg group in TRIUMPH-4 versus 0.7% with placebo, generally mild and rarely causing discontinuation. Rates differed across studies. Calling it unique to retatrutide or declaring its mechanism settled would go beyond these data. [8]

Short trials and topline announcements cannot answer every question about uncommon events or years of exposure. Someone feeling well on a product also cannot determine its purity, concentration, or long-term safety from that experience alone.

Does retatrutide cause muscle loss

Retatrutide should not be described as proven to preserve all muscle. A body-composition substudy in adults with type 2 diabetes found substantial fat reduction alongside loss of lean mass. The proportion of lean mass lost was similar to that seen with other obesity treatments. Lean mass includes more than skeletal muscle, so a scan result is not identical to a measurement of strength or function. [13]

The practical priorities are adequate nutrition, an individualized protein target, and resistance exercise appropriate to the person’s health and abilities. A clinician or registered dietitian can help account for appetite, kidney health, and overall intake. Protein alone does not replace strength training, and neither guarantees that all lean mass will be preserved. [14]

I want patients preparing for surgery to consider how they feel and function as well as what they weigh. A lower number on the scale is not, by itself, evidence that someone is nutritionally ready to heal.

What the liver fat research shows

A small randomized substudy published in Nature Medicine examined people with metabolic dysfunction-associated steatotic liver disease, or MASLD. At 24 weeks, the 12 mg group had an average 82.4% relative reduction in liver fat, and 86% reached a liver-fat level below 5%. These are liver-fat measurements, not proof that cirrhosis was reversed or liver-related deaths prevented. [15]

The authors discuss several possible contributors, including weight loss and direct hepatic effects of glucagon receptor activation. The study does not establish that every improvement was independent of weight loss. [15]

Is retatrutide FDA approved and when could it become available

As of September 16, 2026, retatrutide is not FDA-approved. Lilly’s July 23 announcement states that it plans to submit a Biologics License Application in the first quarter of 2027. A planned submission is not an approval or a confirmed launch date. [1] [9]

Is it a peptide or a biologic? Retatrutide is a peptide, and Lilly has announced a biologics regulatory filing pathway. The terms describe different aspects of the product. Neither classification establishes that it is safer or that it extends life. [3] [9]

There is no confirmed general pharmacy release date to give patients. FDA review, any eventual labeling, supply, price, and insurance coverage remain separate questions. Claims promising a particular launch month or an official retail price should be checked against current manufacturer and FDA information.

Clinical trials expanded access and products sold online

Clinical trials use an investigational medicine under a defined research protocol. Patients interested in participation can search Lilly’s trial directory and discuss eligibility with their treating physician. Recruitment status and criteria vary by study.

Lilly also states that it supports requests for individual-patient expanded access to retatrutide for people meeting specific criteria. This is a limited, physician-led route before approval, not routine prescribing or a way to purchase the drug from a vendor. The treating physician should review Lilly’s current expanded-access information; eligibility and acceptance are not guaranteed. [16]

FDA states that retatrutide cannot be used in compounding under federal law. A seller’s “research use only” wording does not make a product an approved medicine or establish its suitability for injection. [1]

The safety issue is concrete: a buyer may not have reliable confirmation of what is in the vial or at what concentration. A clinical-trial publication about Lilly’s investigational product cannot serve as a quality certificate for a different product. If you are already using something sold as retatrutide, tell your treating clinicians exactly what you have taken and show them the packaging.

Is retatrutide a longevity drug

There is no established evidence that retatrutide extends human lifespan. TRIUMPH-3 reported cardiovascular-event analyses, but their confidence intervals were compatible with both benefit and harm. They do not establish a reduction in heart attacks, strokes, or death. [9]

The separate TRIUMPH-Outcomes study is evaluating major cardiovascular and kidney outcomes. Lilly currently lists an expected end date in February 2029; trial dates can change. Even a favorable result would need to be interpreted in the population and outcomes studied. [17]

Improving weight or a laboratory marker can be valuable without proving that a medicine makes people live longer. “Longevity drug” is therefore a claim that requires evidence beyond the weight-loss headlines.

What I tell patients considering surgery after retatrutide

I am a cosmetic surgeon, not an obesity-medicine specialist, and I do not prescribe retatrutide. My role is to assess the consequences of weight change and whether a patient is ready for an elective operation.

I have consulted with patients who report using products sold as retatrutide outside a trial. Some have described substantial weight loss, good energy, limited side effects, and maintained strength. Some report keeping weight off after stopping. Those accounts explain the interest, but they are not a controlled study. I cannot use them to verify the contents of a product, prove muscle preservation, or predict lasting weight maintenance.

Tell your surgeon and anesthesia team what you are taking

Research has shown that retatrutide can delay stomach emptying. That matters when planning anesthesia because retained stomach contents can increase aspiration concerns. Bring the product information, reported dose, last injection date, symptoms, and details of other medications to the preoperative discussion. [18]

Guidance for approved GLP-1 medicines allows many patients to continue treatment before surgery, with an individualized plan for those at higher risk. It is not a universal clearance for an unapproved or unverified product. Your surgical and prescribing teams should agree on the plan; do not choose a stopping interval from a blog. [19]

Plan around stable weight and adequate nutrition

I will not schedule elective contouring simply because a patient has reached a milestone on the scale. I want a sustainable weight trajectory, adequate nutrition, and a realistic maintenance plan. If substantial further loss is expected, the surgical plan may change.

Significant weight loss can reveal loose abdominal skin, changes in the arms or thighs, and loss of facial volume. The amount varies with the individual; it cannot be predicted from the drug name or a trial average. Depending on the anatomy, the discussion may involve abdominoplasty, a brachioplasty, or facial rejuvenation.

My companion article, Loose Skin After GLP-1 Weight Loss, explains how I distinguish skin laxity, excess skin, and volume loss when discussing surgery.

Frequently asked questions about retatrutide

Is retatrutide the same as GLP-3

People sometimes use that nickname online. The correct description is a GIP, GLP-1, and glucagon receptor agonist. The label on an online product does not verify its contents. [3]

Is retatrutide better than Zepbound

That cannot be settled by comparing headline percentages from separate trials. TRIUMPH-5 is directly comparing retatrutide with tirzepatide, the active ingredient in Zepbound. [12]

Can a doctor prescribe retatrutide now

It is not available as an FDA-approved prescription medicine. Research participation and narrowly defined expanded access are different from routine prescribing. [1] [16]

What is the correct retatrutide dose

There is no FDA-approved retatrutide dosing label. Trial dose groups are research information, not an instruction to start, increase, combine, or reconstitute an online product. [1]

Will weight stay off after stopping retatrutide

Durable maintenance after stopping has not been established for an individual patient. A dedicated retatrutide maintenance study is underway. A personal report of stable weight after stopping cannot answer that longer-term question. [20]

Does retatrutide tighten loose skin

It is not an established skin-tightening treatment. If loose skin remains after weight loss, the next step is to assess skin quality, excess tissue, and weight stability before choosing a procedure.

Questions about body contouring after weight loss

If you have lost significant weight and want to understand what surgery can address, request a consultation with BellaNova Cosmetic Surgery in West Palm Beach or call 561-834-6682. The consultation focuses on surgical options and readiness; BellaNova does not provide retatrutide.

About the author: Albert Carlotti, MD, FAACS is a cosmetic surgeon at BellaNova Cosmetic Surgery in West Palm Beach, Florida, with 25 years of experience in facial and body cosmetic surgery. Read Dr. Carlotti’s background.

This article provides general education and does not establish a doctor–patient relationship or replace individualized medical advice. Approval status and clinical evidence can change. Discuss medication decisions with your treating clinician.

Sources and further reading

Primary research, regulator information, manufacturer announcements, and trial records consulted for this article.

Retatrutide: Results, Side Effects and FDA Status